Sermorelin is a synthetic analog of growth hormone-releasing hormone corresponding to the first 29 amino acids of native GHRH (GHRH 1-29).
🔬 Studied for: GH-Stimulation Research
💊 Also studied for: Aging & Body-Composition Research
🧪 Not FDA-approved — sold strictly for laboratory research
📈 No standardized human dosage established in published literature
Sermorelin is a synthetic analog of growth hormone-releasing hormone corresponding to the first 29 amino acids of native GHRH (GHRH 1-29). It was previously FDA-approved as Geref for diagnostic testing of growth hormone deficiency, though that branded product was later discontinued from the US market for commercial reasons.
Sermorelin binds GHRH receptors in the anterior pituitary, stimulating the natural pulsatile release of growth hormone, working through the same receptor pathway as full-length GHRH and later analogs such as Tesamorelin and CJC-1295.
These are effects Sermorelin has been studied for in available preclinical and early research — not claims about guaranteed outcomes.
Sermorelin's history as an FDA-approved diagnostic agent makes it one of the better-characterized GHRH analogs in the clinical literature, and it remains a reference compound in GH-axis research.
Because GH and IGF-1 output decline with age, Sermorelin has been studied in the context of age-related GH-axis decline, though compounded, non-FDA-regulated Sermorelin products fall outside the approval that once applied to Geref.
The discontinued FDA-approved Geref product was dosed per its clinical labeling for diagnostic GH-stimulation testing; this does not constitute a current recommendation for use of unregulated research material, for which no standardized dosage exists.
Compound X does not provide dosing recommendations. Sermorelin is sold for laboratory research use only and is not intended for human consumption.
When previously marketed as an FDA-approved diagnostic product, documented side effects included injection-site reactions, headache, and flushing. Compounded or research-grade material sourced outside a regulated pharmacy supply chain has not undergone the same quality controls or clinical oversight.
No. Sermorelin is not FDA-approved for any indication and is sold strictly as a research chemical, not a medication or dietary supplement.
GH-Stimulation Research — Sermorelin's history as an FDA-approved diagnostic agent makes it one of the better-characterized GHRH analogs in the clinical literature, and it remains a reference compound in GH-axis research.
In the US, UK, Canada and Australia, Sermorelin is generally sold labeled "for research use only, not for human consumption." It is not approved as a dietary supplement or medication in any of these countries.
Sermorelin's historical FDA approval documentation and clinical data are indexed on PubMed under "Sermorelin GHRH growth hormone."
Compare current prices, purity testing claims and coupon codes across every vendor Compound X tracks.
New guides, vendor comparisons and compound breakdowns every week.